ASH 2016 | EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response

Name: EURO-SKI trial: cessation of TKI treatment in CML patients with deep molecular response
Uploaded: 2016-12-03T00:00:00.000Z
Duration: 6 min 2 s
Description: Press brief by Francois-Xavier Mahon, MD, PhD of University Hospital of Bordeaux, Bordeaux, France, on results of the EURO-SKI trial on cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia (CML) patients with deep molecular response held at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Francois-Xavier Mahon • 3 Dec 2016

ASH 2016

Chronic Myeloid Leukemia

EURO-SKI

Press brief by Francois-Xavier Mahon, MD, PhD of University Hospital of Bordeaux, Bordeaux, France, on results of the EURO-SKI trial on cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia (CML) patients with deep molecular response held at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.